



EUROPEAN COMMISSION

HEALTH & CONSUMERS

DIRECTORATE-GENERAL

Directorate D – Animal Health and Welfare

**Unit D1- Animal health and Standing Committees**

**EUROPEAN UNION REFERENCE LABORATORY (EU-RL) FOR BOVINE TUBERCULOSIS**

**WORK PROGRAMME 2015 – Version 2**



**VISAVET**

**Universidad Complutense de Madrid**

Contact person: Dr. Lucia de Juan (EU-RL Director)  
Address: VISAVET Health Surveillance Centre  
Universidad Complutense de Madrid  
Avda. Puerta de Hierro s/n  
28040 Madrid, Spain  
Phone number: +34 913943992  
Fax number: +34 913943795  
E-mail address: [dejuan@visavet.ucm.es](mailto:dejuan@visavet.ucm.es)

## Table of contents

<b>A. MAIN ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2015.....</b>	<b>4</b>
1. Potency test of bovine PPDs.....	4
2. Harmonized protocol for IFN- $\gamma$ in the EU.....	4
3. Update in Mycobacteria recovery from different culture media.....	5
4. Molecular detection of <i>Mycobacterium tuberculosis</i> complex in animal tissues.....	5
5. Comparative tests.....	6
6. Open databases.....	7
6.1. MALDI BIOTYPER for the identification of mycobacterial species.....	7
6.2. Molecular database.....	7
7. European Standard.....	8
8. Missions.....	9
9. Training of personnel.....	9
10. Workshop.....	10
<b>B. OTHER ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2015.....</b>	<b>10</b>
1. Preparation, control and supply of laboratory material (including in house spoligotyping membranes) and protocols.....	11
2. Collection of representative samples (tissue samples, strains, DNA, serum/plasma)...	11
3. Isolation, identification and typing of mycobacteria.....	11
4. World Wide Web page update.....	11
5. Technical assistance to the Commission and NRLs and participation with EFSA and international organizations (bovine tuberculosis subgroup of the Task Force, OIE). 11	11
6. Dissemination (presentations at international and national congresses or conferences, and publication in international and national journals).....	11
7. Keeping abreast of developments (papers, conferences, training courses, reports, legislation, etc.) and research activities (collaboration with NRLs, participation in research projects, etc.).....	11
8. Technical and financial management of the activities included in the work programme.....	11

The purpose of the work programme is to cover the objectives (general, specific and operational) defined in the Annex to the Commission Implementing Decision establishing the work programme for the year 2015 on financial contribution to the European Union reference laboratories, taking into account the responsibilities and tasks defined in the Annex II to Commission Regulation (EC) No 415/2013 regarding the EU-RL for Bovine Tuberculosis:

1. To coordinate, in consultation with the Commission, the methods employed in the Member States for diagnosing bovine tuberculosis.
2. To facilitate the harmonization of techniques throughout the Union, in particular specifying standard test methodologies.
3. To organize workshops for the benefit of national reference laboratories as agreed in the work programme and estimated budget referred to in Article 2 of Implementing Regulation (EU) No 926/2011, including training of experts from the Member States and, as appropriate, from third countries, in new analytical methodologies.
4. To provide technical assistance to the Commission and, upon its request, to participate in international fora relating to the diagnostic of bovine tuberculosis, concerning in particular the standardization of analytical methods and their implementation.
5. To perform research activities and, whenever possible, coordinate research activities directed towards the improved control and eradication of bovine tuberculosis.

## A. MAIN ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2015.

### 1. Potency test of bovine PPDs.

Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network.

**Description:** The Purified Protein Derivatives (PPD or tuberculin) are the reagents for the official *in vivo* and *in vitro* diagnostic assays based on cell-mediated immune response for the diagnosis of bovine tuberculosis. The biological potency of a PPD is estimated by comparing the size of the reaction elicited by an intradermal inoculation of the test tuberculin and an International Standard in naturally infected cattle or experimentally infected or sensitized guinea pigs as defined in the European Pharmacopoeia and the OIE Manual.

**Objectives:** A comparative test is programmed at the end of 2014 including the NRLs that perform biological testing. Depending on the results, studies towards standardization of the protocol will be performed with the final objective of setting up a standardized protocol for performing potency test of tuberculins in guinea pigs. Moreover, tuberculins used in the Member States for bovine diagnosis will be tested to determine their biological potency.

**Expected outputs:** a) Standard protocol to determine the biological potency of the tuberculin in guinea pigs; b) Define the potency of the tuberculins produced by different manufacturers all over Europe to check if they meet the international standards to provide a correct and reliable diagnosis of bovine tuberculosis.

### 2. Harmonized protocol for IFN- $\gamma$ in the EU.

Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network.

**Description:** The IFN- $\gamma$  test is used for detection of the IFN- $\gamma$  against *M. bovis* and *M. avium* antigens together with the skin test to detect a higher number of infected animals. During 2012, a Scientific Opinion on the use of gamma interferon test for the diagnosis of bovine tuberculosis [EFSA Journal 2012;10(12):2975] was published including some recommendations regarding harmonization of the protocol as well as the study of factors that may affect the test specificity. In the case this technique is incorporated to the EU legislation as well as the OIE Manual for other purposes (ie. establishment of freedom after outbreaks, confirmatory diagnosis of clinical cases, estimate prevalence of infection, etc.), there is a necessity to address the recommendations included in this opinion to have a robust, safe and reliable accepted protocol by all the MSs NRLs.

**Objectives:** To address the recommendations included in the EFSA Scientific Opinion on the use of gamma interferon test for the diagnosis of bovine tuberculosis (harmonized protocol, influence of factors-age, production system, etc.).

**Expected outputs:** a) To define the performance of the IFN- $\gamma$  test when evaluating different factors under different epidemiological situations; b) To set up a harmonized protocol for IFN- $\gamma$  detection in the EU in consensus with all the NRLs.

### 3. Update in Mycobacteria recovery from different culture media.

Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network.

**Description:** In 2013 the EU-RL performed a study to define the sensitivity of different culture media to be able to recommend the media that should be used for isolation of Mycobacteria in the Member States. The conclusion of this study was to use a combination of culture media (Lowenstein Jensen with pyruvate or glycerol, MGIT, Coletsos, Middlebrook 7H11) for the rapid detection of positive samples with the vigorous growth. The drawbacks of this study were that only four *Mycobacterium* spp. were included and all of them were from the same origin (Spanish isolates).

**Objectives:** The objective of this study will be to collect a representative number of isolates from the Member States (*M. bovis* and *M. caprae*) and to subculture them in the selection of culture media identified in the previous study. In this sense, it will be possible to identify the culture media that shows the best results regarding isolation of *M. bovis* and *M. caprae*.

**Expected outputs:** Recommended culture media for microbiological protocol within Europe.

### 4. Molecular detection of *Mycobacterium tuberculosis* complex in animal tissues.

Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network.

**Description:** During 2014 the EU-RL has developed an extraction protocol combined to a Real Time PCR assay for the detection of members of the *Mycobacterium tuberculosis* complex (MTBC) in animal tissues. The assay demonstrated remarkable sensitivity and specificity when compared to culture. For 2015 the EU-RL is seeking to further evaluate the performance of this protocol and finally validate it by performing studies on the specificity, repeatability and reproducibility of the assay.

**Objectives:** Main objectives of this task will be a) the definition of the sensitivity of the test by comparing it with skin test, pathology and culture, b) the estimation of the specificity by applying it on tuberculosis free herds, c) the evaluation of the repeatability by intralaboratory assays, and d) the estimation of the reproducibility in cooperation with NRLs that already apply molecular techniques for the detection of members of MTBC in animal tissues.

**Expected outputs:** The creation of a robust and efficient molecular protocol for the detection of members of the MTBC in animal tissues that once thoroughly validated could be exploited in the diagnosis of bovine tuberculosis.

## 5. Comparative tests.

Operational objective 1 and 2: To ensure the development and use of high quality analytical methods across the EU-RL network; and to maintain appropriate level of proficiency testing ensuring efficiency of control analysis methods.

**Description:** During 2015, two ring trials will be organized regarding microbiological culture and potency testing of PPDs. The rationales for organizing these ring trials are: a) bacteriological culture is defined as the diagnostic tool for confirming the disease and it is still considered as the gold standard. In this ring trial, the NRLs will adapt their culture media selection in accordance with the results obtained in the EU-RL activity "Mycobacteria recovery from different culture media"; and b) the EU-RL is performing studies in guinea pigs to determine the biological potency of the tuberculins used in the different Member States for the diagnosis of bovine tuberculosis. Although guidelines for the protocol are described in the OIE manual, some modifications have been encountered between NRLs. Although a comparative test is going to be organized in 2014, only a few PPDs can be tested in each ring trial and more information regarding protocols as well as performance of NRLs is needed. Participation of producers will be considered taking into account the results obtained in the first ring trial.

**Objectives:** To organize two ring trials for all the NRLs: a) Evaluation of the isolation of mycobacteria by microbiological culture. A set of tissue samples will be sent to NRLs to perform the bacteriological culture to define the positive and negative samples; b) Evaluation of the methodology for determination of biological potency of the PPD in guinea pigs. Blinded PPDs will be sent to determine the biological potency in each NRL.

**Expected outputs:** a) Evaluation of the methodology for bacteriological culture; b) Knowledge of the methodology for determination of the biological potency of tuberculins in guinea pigs and comparison of results.

## 6. Open databases.

Operational objective 1 and 3: To ensure the development and use of high quality analytical methods across the EU-RL network; and to ensure the availability of scientific and technical assistance provided by the EU-RLs.

### 6.1. MALDI BIOTYPER for the identification of mycobacterial species.

**Description:** MALDI TOF MS is proposed as an extremely promising approach for the identification of bacterial isolates based on their proteomic profile. This technique reduces considerably the time and resources needed for identification thus, rendering it ideal for the identification of mycobacterial species. The main drawbacks regarding mycobacterial identification by MALDI BIOTYPER today are the absence of an effective protocol for the extraction of high quality proteins from mycobacteria and the relatively small number of entries (mainly of human interest) in the commercially available platforms.

**Objectives:** a) Further elaboration and validation of the extraction protocol that the EU-RL has developed during 2014; and b) creation of a database, which will include several entries of the main mycobacterial species of veterinary interest.

**Expected outputs:** a) Production of a protein extraction protocol for the identification of mycobacterial species by MALDI TOF MS. This protocol once validated could be proposed as a reference standard protocol for the detection of mycobacteria by MALDI TOF MS; and b) creation of new mycobacterial entries of veterinary interest for the BIOTYPER database which will permit a more efficient and precise identification of mycobacterial species. The above-mentioned database could be the base for the creation of a European database with spectra of mycobacterial isolates, available to all Member States.

### 6.2. Molecular database.

**Description:** Nowadays, DVR-spiligotyping is still considered as the routine molecular characterization protocol for members of the MTBC. Two main databases are available: the SITVIT Database (Public Health, Demay et al. 2012) and the mbovis.org (Animal Health, Smith et al. 2012). During 2014, the EU-RL has discussed with the managers of both databases (Dr. Smith-APAH and Dr. Rastogi-Institute Pasteur Guadalupe) the future possibility to unify/connect both databases (*M. bovis*/*M. caprae*) to assist the epidemiological studies of bovine tuberculosis. The first step will be to migrate the mbovis.org database to the VISAVET server and set it up in the EU-RL website (scheduled for 2015). This database will record the *M. bovis*/*M. caprae* isolates all over the world. In the second step (scheduled for 2016-2017) a specific European database

will be designed (mbovisEU.org). For this objective, the EU-RL will contact the NRLs to collect all the characterization data regarding *M. bovis*/*M. caprae* isolates in Europe. This will allow the registration of the isolates identified in each Member State and therefore facilitate future epidemiological studies. The last step (scheduled 2017) will be to include the *M. bovis*/*M. caprae* isolates identified in human through the Public Health NRLs. Bovine tuberculosis is a zoonosis and therefore a record of the human strains link to the animal ones will assist the epidemiological studies all over Europe.

**Objectives:** To migrate the mbovis.org database to the VISAVET server (EU-RL website). This objective is the first step towards the final task of integrating both databases (Animal and Public Health) including a specific European database (ie. mbovisEU.org) that will be scheduled in the future activities for the EU-RL (workprogramme 2016).

**Expected outputs:** Maintenance of a molecular database to guarantee the standardization of nomenclature for DVR-spoligotyping profiles allowing epidemiological studies.

## 7. European Standard.

Operational objective 1: To ensure the development and use of high quality analytical methods across the EU-RL network.

**Description:** The international standard (IS) (NIBSC, United Kingdom) is used as a control in the *in vivo* testing of the tuberculins although its stock is limited and questions regarding its actual quality are arising. It is of critical importance to have a standard available for NRLs since the determination of biological potency of the PPDs used all over Europe are based on the results obtained when comparing the test tuberculin with the standard one. For this reason, the EU-RL has been focusing in studying the characteristics needed for a future European Standard (ES) for *in vivo* testing of the tuberculins. The use of this European Standard within Member States will be defined together with the European Commission once the ES is ready to be used in laboratory trials.

**Objectives:** The main objective would be the distribution of a European Standard tuberculin to the stakeholders for their potency testing studies to avoid consuming the IS stock. During 2014, a ring trial on PPD testing will be performed including the International Standard as a reference. In this sense, the biological potency (IU/ml) of a tested tuberculin will depend on the quality of the IS. Depending the results of this comparative test, during 2015 a potency test in guinea pigs will be scheduled to test



the potency and define the suitability of the European Standard to perform the potency studies in comparison with the International Standard.

**Expected outputs:** To test the European Standard *in vivo* (guinea pigs) to guarantee its suitability as an internal control in the potency test studies. The European Standard will be tested in the EU-RL biological potency studies together with the 2015 ring trial.

## 8. Missions.

Operational objective 1, 2 and 3: To ensure the development and use of high quality analytical methods across the EU-RL network; to maintain appropriate level of proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs.

**Description:** If requested by the EC or under specific circumstances, the EU-RL staff will visit the European Commission or NRLs. During 2015, a visit to the French NRL (OIE Reference Laboratory for Bovine Tuberculosis) is scheduled to organize the direct extraction protocol validation and to discuss the *in vivo* PPDs testing. Moreover, the EU-RL staff visits: a) cattle farms to perform field studies (MID-test, IFN- $\gamma$ , serology) and collect samples (blood) for the EU-RL samples bank; b) slaughterhouses to collect tissue samples (lymph nodes and organs) to perform the bacteriological culture and/or to be included in the sample reference bank; and c) CVO offices to discuss sampling of cattle farms. One objective of the EU-RL is to keep abreast of developments mainly in diagnosis and epidemiology of tuberculosis and therefore the EU-RL staff attend congresses, workshops, training courses and they are updated through reports from experts, legislation, scientific papers, etc.

**Objectives:** a) To assist the EC/NRLs; b) To collect biological samples (farm/slaughterhouse); and c) To attend conferences and training courses (ie. Introduction to Next Generation Sequencing, UK).

**Expected outputs:** a) Technical advice/collaboration with EC/NRLs; b) Collection of samples for field studies included in the WP; and c) Scientific training of the EU-RL staff.

## 9. Training of personnel

Operational objective 1, 2 and 3: To ensure the development and use of high quality analytical methods across the EU-RL network; to maintain appropriate level of proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs.

**Description:** As included in the Annex II of the Commission Regulation (EC) No 415/2013, the EU-RL must train experts from the Member States. These training mobilities are

designed to teach new methodologies as well as accreditation process and the workflow in a BSL 3.

**Objectives:** Short visits for two National Reference Laboratories to allow the establishment of new protocols and techniques in their laboratory of origin. The trainee will present the activities of his/her NRL to the EU-RL and will submit a brief report after the visit.

**Expected outputs:** Training of NRL staff in mycobacteria protocols (culture, PCR, DVR-spoligotyping, MIRU-VNTR, IFN- $\gamma$  test) and accreditation system.

#### **10. Workshop.**

Operational objective 1, 2 and 3: To ensure the development and use of high quality analytical methods across the EU-RL network; to maintain appropriate level of proficiency testing ensuring efficiency of control analysis methods; and to ensure the availability of scientific and technical assistance provided by the EU-RLs.

**Description:** A workshop is an annual meeting for information and coordination for all National Reference Laboratories.

**Objectives:** To organize a workshop with all the NRLs to present the information regarding the activities performed by the EU-RL in the previous years and to understand the priorities and necessities regarding bovine tuberculosis diagnosis of the different NRLs.

**Expected outputs:** Annual meeting to share information regarding EU-RL activities with the NRLs.

#### **B. OTHER ACTIVITIES OF THE EU-RL FOR BOVINE TUBERCULOSIS FOR 2015.**

Operational objective 1, 2, 3 and 4: To ensure the development and use of high quality analytical methods across the EU-RL network; to maintain appropriate level of proficiency testing ensuring efficiency of control analysis methods; to ensure the availability of scientific and technical assistance provided by the EU-RLs; and to ensure a sound and efficient management of EU-RL funding cycle.

The following tasks will remain permanent activities of the EU-RL for 2015.

1. Preparation, control and supply of laboratory material (including in house spoligotyping membranes) and protocols.
2. Collection of representative samples (tissue samples, strains, DNA, serum/plasma).
3. Isolation, identification and typing of mycobacteria.
4. World Wide Web page update.
5. Technical assistance to the Commission and NRLs and participation with EFSA and international organizations (bovine tuberculosis subgroup of the Task Force, OIE).
6. Dissemination (presentations at international and national congresses or conferences, and publication in international and national journals).
7. Keeping abreast of developments (papers, conferences, training courses, reports, legislation, etc.) and research activities (collaboration with NRLs, participation in research projects, etc.).
8. Technical and financial management of the activities included in the work programme.